Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve J Chadban

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Transplantation|July 22, 2021
The Authors' Reply: Type 2 Diabetes and Simultaneous Pancreas-kidney TransplantationSteve J Chadban, Greg A Knoll
Transplantation|October 24, 2017
The Authors' ReplyStephen I Alexander, Philip A Clayton, Steve J Chadban
Kidney360|April 4, 2022
Global Perspective on Kidney Transplantation: AustraliaMelanie L R Wyld, Kate R Wyburn, Steve J Chadban
Nephrology (Carlton, Vic.)|February 26, 2013
Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluriaTony K Kwan, Steve J Chadban, Paul R McKenzie, et al.
Nephrology (Carlton, Vic.)|March 27, 2015
Dangers of broth after transplantationShikha Aggarwal, Louisa Sukkar, Lucy Wynter, et al.
Nephrology (Carlton, Vic.)|May 18, 2010
Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipientsWai H Lim, Steve J Chadban, Scott Campbell, et al.
Transplantation|December 3, 2014
The expectations and attitudes of patients with chronic kidney disease toward living kidney donor transplantation: a thematic synthesis of qualitative studiesCamilla S Hanson, Steve J Chadban, Jeremy R Chapman, et al.
Nephrology (Carlton, Vic.)|July 2, 2019
The experiences and impact of being deemed ineligible for living kidney donation: Semi-structured interview studyAngelique F Ralph, Steve J Chadban, Phyllis Butow, et al.
Transplantation|November 26, 2009
Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipientsWai H Lim, Sean H Chang, Steve J Chadban, et al.
Transplant Immunology|July 30, 2008
Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine AHungta Ko, Brett D Hambly, Josette M Eris, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Transplantation|July 22, 2021
The Authors' Reply: Type 2 Diabetes and Simultaneous Pancreas-kidney TransplantationSteve J Chadban, Greg A Knoll
Transplantation|October 24, 2017
The Authors' ReplyStephen I Alexander, Philip A Clayton, Steve J Chadban
Kidney360|April 4, 2022
Global Perspective on Kidney Transplantation: AustraliaMelanie L R Wyld, Kate R Wyburn, Steve J Chadban
Nephrology (Carlton, Vic.)|February 26, 2013
Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluriaTony K Kwan, Steve J Chadban, Paul R McKenzie, et al.
Nephrology (Carlton, Vic.)|March 27, 2015
Dangers of broth after transplantationShikha Aggarwal, Louisa Sukkar, Lucy Wynter, et al.
Nephrology (Carlton, Vic.)|May 18, 2010
Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipientsWai H Lim, Steve J Chadban, Scott Campbell, et al.
Transplantation|December 3, 2014
The expectations and attitudes of patients with chronic kidney disease toward living kidney donor transplantation: a thematic synthesis of qualitative studiesCamilla S Hanson, Steve J Chadban, Jeremy R Chapman, et al.
Nephrology (Carlton, Vic.)|July 2, 2019
The experiences and impact of being deemed ineligible for living kidney donation: Semi-structured interview studyAngelique F Ralph, Steve J Chadban, Phyllis Butow, et al.
Transplantation|November 26, 2009
Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipientsWai H Lim, Sean H Chang, Steve J Chadban, et al.
Transplant Immunology|July 30, 2008
Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine AHungta Ko, Brett D Hambly, Josette M Eris, et al.
Pageof 3